THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook Weekly Brief
Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Pharma Tech Outlook
Andrew Brown, Chief Commercial OfficerA technical contract research organization (CRO), Sirona Dx specializes in high complexity genomics and proteomics services to support pharmaceutical companies with their drug discovery and development programs. Be it for exploratory testing and biomarker development, or clinical trials and companion diagnostics, Sirona Dx offers the latest technologies and guides clients to the assays and platforms that best match their requirements.
Sirona Dx is effectively accelerating the pace of immunotherapy and targeted therapy development by bridging the silos between the pharma and life sciences tools industry. What differentiates the company from other players is its deep relationships with leading life science tools and platform providers which allows pharma clients to access cutting-edge technologies even before they are commercially available. In contrast to its competitors who wait for the latest platforms to arrive as the finished product, Sirona Dx embraces new technology at an early stage, often assisting with product development and producing a win for all parties.
A good example of this innovative approach is in the area of multiplexed tissue imaging where Sirona Dx is a pioneer and provides comprehensive end-to-end solutions for spatially-resolved, highly multiplexed biomarker analysis. Leveraging premium technologies like Imaging Mass Cytometry (developed by Fluidigm) and CODEX ultra-high plex imaging (developed by Akoya Biosciences), pharmaceutical companies are no longer constrained by the limitations of traditional IHC and can image up to 40 biomarkers in the same tissue section at single cell resolution.
“Our highly optimized 34 marker Immune Portrait TME Panel, developed for comprehensive analysis of the tumor microenvironment at a sub-cellular resolution, is a work-horse for many of our clients,” remarks Andrew Brown, PhD, Chief Commercial Officer at Sirona Dx. Sirona Dx also utilizes Mass Cytometry for in-depth characterization of immune cell subsets in suspension from whole blood and PBMCs, enabling simultaneous assessment of more than 40 parameters in a single sample.
Our CLIA accredited, technology agnostic laboratory offers a comprehensive suite of specialized genomics and proteomics services to deeply profile the immune system and reveal the interplay with the tumor/tissue microenvironment
In addition to leading edge proteomics services, Sirona Dx also supports clients with a portfolio of specialized genomics capabilities including a menu of immune expression profiling assays, unique DNA/RNA extraction methodologies and more. “Our CLIA accredited, technology agnostic laboratory offers a comprehensive suite of specialized genomics and proteomics services to deeply profile the immune system and reveal the interplay with the tumor/tissue microenvironment,” adds Brown. With integrated, leading edge technologies, Sirona Dx can produce comprehensive, multi-omic analysis in a way that is rarely seen in a single laboratory. Be it support with gene expression, microRNA profiling, next-generation sequencing, rare cell enrichment or high parameter single-cell proteomics, Sirona Dx emerges as an essential pharma partner.
Sirona Dx’s deep technical expertise and strong partnerships with key platform providers have also propelled the company into a supporting role during the ongoing COVID-19 crisis. The company draws on its knowledge of high-parameter Mass Cytometry and Imaging Mass Cytometry to analyze immune cell frequencies and activation responses in patients’ blood and lung tissue. Sirona Dx is also collaborating closely with leading platform providers to offer a faster, more accurate and efficient RNA testing service for COVID-19 infection, leveraging the power of microfluidics for rapid testing of thousands of samples per day.
Since its inception in 2016, Sirona Dx has assembled an extremely strong team and has integrated an impressive suite of capabilities. “Today over 30 pharma and biotech clients rely on Sirona Dx to advance their immune therapy assets. We will continue to be guided by our pharma clients, ensuring that we understand their challenges and are able to support their current and future requirements”, says Brown. In parallel Sirona Dx will continue to work closely with life science tools partners and help them bring new technologies to market that are fit for purpose. “This is an incredibly exciting time for the advancement of molecular and immune therapies. Here at Sirona Dx we are uniquely positioned to assist and are enthusiastically committed to the cause”, says Brown.
Company
Sirona Dx
Management
Andrew Brown, Chief Commercial Officer
Description
Sirona Dx is a technical CRO that is bridging silos between diagnostics manufacturers and translational clinical research, thereby accelerating the pace of immunotherapy and targeted therapy development. Be it for exploratory testing and biomarker development, or clinical trials and companion diagnostics, Sirona Dx offers the latest technologies and guides clients to the assays and platforms that best match their requirements. What differentiates the company from other players is its deep relationships with leading life science tools and platform providers which allows pharma clients to access cutting-edge technologies even before they are commercially available
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230223005618/en/
Lunaphore’s COMET™ platform is the only fully automated, high-throughput, hyperplex platform with superior tissue profiling capabilities. Its capacity allows the generation of high-quality and reproducible data on large cohorts of samples in days. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, enabling customers to use their trusted antibodies and making panel design fast and flexible. Thanks to its versatility, COMET™ has a wide range of research applications across multiple disciplines and all stages of research and drug development.
Sirona Dx is a highly-specialized technical CRO and pioneer of single-cell and spatial biology, having launched ultra-high parameter, multiplexed single-cell services to biopharma in 2018. Their innovative, technology-agnostic service capabilities contributed to their selection as a Top 10 CRO of 2021 by Medhealth Outlook.
“Platform selection is one of the most important decisions to make when developing multiplexed tissue imaging panels for our clients”, said Andrew Brown, Ph.D., Chief Commercial Officer at Sirona Dx. “We are extremely pleased to partner with Lunaphore to integrate the COMET™ platform into our spatial-omics operations. The ability to select off-the-shelf, label-free primary antibodies is highly advantageous and reduces the time required to develop robust, highly reproducible assays.
“The deployment of COMET™ at Sirona Dx is particularly meaningful for Lunaphore as it helps to address the large demand from US-based biotech and biopharmaceutical companies to access highly reproducible hyperplex data,” said Déborah Heintze, Chief Marketing Officer at Lunaphore. “Furthermore, Sirona Dx’s CLIA certification and deep understanding of pharmaceutical regulatory requirements add significant value for scientists looking to adopt spatial biology tools to accelerate translational research”.